Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808753 | 0.99 | ABCB1 (0.46) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL17413919 | 0.92 | ABCB1 (0.45) | USP2CFTRPAX8ATMGOPC | |
| Hydrochloric Acid SCHEMBL5605911 | 0.92 | USP2 (0.47) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL6056007 | 0.91 | ABCB1 (0.47) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL13653629 | 0.91 | ABCB1 (0.47) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL17919671 | 0.88 | ABCB1 (0.42) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL18368213 | 0.87 | ABCB1 (0.41) | USP2CFTRPAX8ATMGOPC | |
| Hydrochloric Acid SCHEMBL28449515 | 0.86 | USP2 (0.43) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL2732905 | 0.85 | ABCB1 (0.43) | USP2CFTRPAX8ATMGOPC | |
| SCHEMBL6056220 | 0.85 | ABCB1 (0.43) | USP2CFTRPAX8ATMGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415987-B2 | Methods and composition for producing and using immune cells and stem cells for cell-based therapies | ANGELES THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | claimed |
| EP-3484496-B1 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | UNIV SOUTHERN CALIFORNIA (US) | 2023-12-27 | — | — | EP | claimed |
| US-20220387502-A1 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | ANGELES THERAPEUTICS, INC. | 2022-12-08 | — | — | US | claimed |
| EP-3687553-A1 | NOVEL PLATFORMS FOR CO-STIMULATION, NOVEL CAR DESIGNS AND OTHER ENHANCEMENTS FOR ADOPTIVE CELLULAR THERAPY | University of Southern California (US) | 2020-08-05 | — | — | EP | claimed |
| EP-3548055-A2 | SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF | University of Southern California (US) | 2019-10-09 | — | — | EP | claimed |
| US-20190209614-A1 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-07-11 | — | — | US | claimed |
| WO-2019067805-A1 | NOVEL PLATFORMS FOR CO-STIMULATION, NOVEL CAR DESIGNS AND OTHER ENHANCEMENTS FOR ADOPTIVE CELLULAR THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-04-04 | — | — | WO | claimed |
| WO-2018102795-A2 | SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-06-07 | — | — | WO | claimed |
| JP-2004518766-A | — | — | 2004-06-24 | — | — | JP | claimed |
| US-20030212126-A1 | Bactericides, viricides; anticancer agents, antitumor agents | CELMED BIOSCIENCES INC. (CA) | 2003-11-13 | — | — | US | claimed |
| EP-1276734-A1 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF | THERATECHNOLOGIES INC. (CA) | 2003-01-22 | — | — | EP | claimed |
| WO-2002079183-A1 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF | THERATECHNOLOGIES INC. (CA) | 2002-10-10 | — | — | WO | claimed |
| EP-0773794-B1 | NOVEL RHODAMINE DERIVATIVES FOR PHOTODYNAMIC THERAPY OF CANCER AND IN VITRO PURGING OF THE LEUKEMIAS | UNIV MONTREAL (CA) | 2001-06-20 | — | — | EP | claimed |
| US-5773460-A | Rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias | UNIVERSITE DE MONTREAL (CA) | 1998-06-30 | — | — | US | claimed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12415987-B2 | Methods and composition for producing and using immune cells and stem cells for cell-based therapies | ANGELES THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12269859-B2 | Synthetic immune receptors and methods of use thereof | ANGELES THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-5556992-A | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias | UNIVERSITE DE MONTREAL (CA) | 1996-09-17 | — | — | US | disclosed |
| US-5556992-A | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias | UNIVERSITE DE MONTREAL (CA) | 1996-09-17 | — | — | US | disclosed |
| WO-1996007431-A1 | NOVEL RHODAMINE DERIVATIVES FOR PHOTODYNAMIC THERAPY OF CANCER AND IN VITRO PURGING OF THE LEUKEMIAS | UNIVERSITE DE MONTREAL (CA) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212126-A1 | Bactericides, viricides; anticancer agents, antitumor agents | TPD52L2, AARS1, C1S | SCN1A 2932/4885SCN2A 3742/4885SCN3A 3481/4885 |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | SCN1A 1070/4885SCN2A 1420/4885SCN3A 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.